Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus: A Multicenter, Randomized Controlled Trial

Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus: A Multicenter, Randomized Controlled Trial

Background. The aim of this open-label, multicenter, randomized controlled study was to investigate whether the life cycle pharma (LCP)-tacrolimus compared with the extended-release (ER)-tacrolimus formulation results in a difference in the prevalence of posttransplant diabetes, hypertension and chr...

Full description

Bibliographic Details
Main Authors: Midas B. Mulder, PharmD, Bart van Hoek, MD, PhD, Wojtek G. Polak, MD, PhD, Ian P.J. Alwayn, MD, PhD, Brenda C.M. de Winter, PharmD, PhD, Sarwa Darwish Murad, MD, PhD, Elke Verhey-Hart, BSc, Lara Elshove, MSc, Nicole S. Erler, Dipl-Stat, PhD, Dennis A. Hesselink, MD, PhD, Caroline M. den Hoed, MD, PhD, Herold J. Metselaar, MD, PhD
Format: Article
Language:English
Published: Wolters Kluwer 2024-04-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001612

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001612

Similar Items